

with the Magnuson-Stevens Fishery Conservation and Management Act, those issues may not be the subject of formal Council action during the meeting. Council action will be restricted to those issues specifically identified in the agenda listed in this notice.

### Special Accommodations

These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Helen Allen, 907-271-2809, at least 5 working days prior to the meeting date.

Dated: November 12, 1997.

#### Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 97-30254 Filed 11-17-97; 8:45 am]

BILLING CODE 3510-22-F

## DEPARTMENT OF COMMERCE

### National Oceanic and Atmospheric Administration

[I.D. 111297C]

#### Marine Mammals (File No. 758-1431)

**AGENCY:** National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

**ACTION:** Issuance of scientific research permit no. 758-1431.

**SUMMARY:** Notice is hereby given that Dr. Kimberlee Beckmen, Institute of Arctic Biology, University of Alaska Fairbanks, P.O. Box 757000, Fairbanks, AK 99775-7000, is hereby authorized to conduct research on two captive, adult Northern fur seals (*Callinorinus ursinus*).

**ADDRESSES:** The permit and related documents are available for review upon written request or by appointment in the following offices:

Permits Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13130, Silver Spring, MD 20910 (301/713-2289);

Regional Administrator, Northwest Region, NMFS, NOAA, 7600 Sand Point Way, NE., BIN C15700, Building 1, Seattle, WA 98115-0070 (206/526-6150);

Regional Administrator, Alaska Region, NMFS, NOAA, P.O. Box 21668, Juneau, AK 99802-1668 (907/586-7221).

**SUPPLEMENTARY INFORMATION:** On September 29, 1997, notice was published in the **Federal Register** (62 FR 50907) that the above-named

applicant had submitted a request for a scientific research permit to blood sample and vaccinate two captive, adult Northern fur seals with a benign antigen, Fort Dodge tetanus toxoid, for the purpose of scientific research at a U.S. facility that is holding captive Northern fur seals. The requested permit has been issued under the authority of the Marine Mammal Protection Act of 1972, as amended (16 U.S.C. 1361 *et seq.*), the Fur Seal Act of 1966, as amended (16 U.S.C. 1151 *et seq.*), and the regulations governing the taking and importing of marine mammals (50 CFR Part 216).

Dated: November 12, 1997.

#### Ann D. Terbush,

Chief, Permits and Documentation Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 97-30255 Filed 11-17-97; 8:45 am]

BILLING CODE 3510-22-F

## DEPARTMENT OF COMMERCE

### National Oceanic and Atmospheric Administration

[I.D. 102497A]

#### Marine Mammals, Endangered or Threatened Species, Scientific Research Permit (File No. 473-1433); Correction

**AGENCY:** National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

**ACTION:** Receipt of application; correction.

**SUMMARY:** The National Marine Fisheries Service published a document in the **Federal Register** of October 31, 1997, concerning an application to take several species of cetaceans for purposes of scientific research. The document inadvertently omitted that the proposed takes are to be conducted on an annual basis.

**FOR FURTHER INFORMATION CONTACT:** Jeannie Drevenak, Permits Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13824, Silver Spring, MD 20910 (301/713-2289).

#### Correction

In the **Federal Register** issue of October 31, 1997, in FR Doc. 97-28833, on page 58943, in the first column, correct the second paragraph under the **SUPPLEMENTARY INFORMATION** caption by inserting the word "annually" before the word "from" in line four and the word "annually" between the words "physalus" and "may" in line 17.

Dated: November 12, 1997.

#### Ann D. Terbush,

Chief, Permits and Documentation Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 97-30159 Filed 11-17-97; 8:45 am]

BILLING CODE 3510-22-F

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)

**AGENCY:** Office of the Secretary, DoD.

**ACTION:** Notice of extension of cancer treatment clinical trials demonstration project.

**SUMMARY:** This notice is to advise interested parties of a one-year extension of a demonstration project in which the DoD provides CHAMPUS reimbursement for eligible beneficiaries who receive cancer treatment under approved National Institutes of Health, National Cancer Institute (NCI) clinical trials. Participation in these clinical trials will improve access to promising cancer therapies for CHAMPUS eligible beneficiaries when their conditions meet protocol eligibility criteria. DoD financing of these procedures will assist in meeting clinical trial goals and arrival at conclusions regarding the safety and efficacy of emerging therapies in the treatment of cancer. At this time, there is insufficient demonstration data for a full evaluation of costs associated with enrollment in clinical trials. Extending the demonstration for an additional year will show sufficient time for patient accrual to clinical trials and collection of data which allows for comprehensive economic analysis. This demonstration also affects TRICARE, the managed health care program that includes CHAMPUS. This demonstration project is under the authority of 10 U.S.C., section 1092.

**EFFECTIVE DATE:** January 1, 1998.

**FOR FURTHER INFORMATION CONTACT:** Cynthia P. Speight, Office of the Assistant Secretary of Defense (Health Affairs), (703) 697-8975.

#### SUPPLEMENTARY INFORMATION:

##### Background

On January 24, 1996, the Department provided notice in the **Federal Register** (61 FR 1899) of an extension of an existing demonstration for breast cancer treatment clinical trials to include all cancer treatment clinical trials under approved National Cancer Institute (NCI) clinical trials. The demonstration purpose is to improve beneficiary access